Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
Birmingham, AL
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
Aurora, CO
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
Fairfield, CT
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
Fairfield, CT
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
East Lansing, MI
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
East Lansing, MI
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
Houston, TX
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Clinical Research Facility
mi
from
Burlington, VT
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated:  1/19/2016
Research Site
mi
from
Parkville,
Atacicept in Subjects With Optic Neuritis
A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course
Status: Enrolling
Updated: 1/19/2016
Research Site
mi
from
Parkville,
Click here to add this to my saved trials
iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery
A Comparative Study of Icare Rebound Tonometry With Other Tonometry Modalities in Patients Following Vitreoretinal Surgery.
Status: Enrolling
Updated:  1/20/2016
Duke University Eye Center
mi
from
Durham, NC
iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery
A Comparative Study of Icare Rebound Tonometry With Other Tonometry Modalities in Patients Following Vitreoretinal Surgery.
Status: Enrolling
Updated: 1/20/2016
Duke University Eye Center
mi
from
Durham, NC
Click here to add this to my saved trials
Erythrocyte Ghost Mediated Retinal Diagnosis
Erythrocyte Ghost Mediated Retinal Diagnosis
Status: Enrolling
Updated:  1/20/2016
Northshore LIJ/MEETH Campus
mi
from
New York, NY
Erythrocyte Ghost Mediated Retinal Diagnosis
Erythrocyte Ghost Mediated Retinal Diagnosis
Status: Enrolling
Updated: 1/20/2016
Northshore LIJ/MEETH Campus
mi
from
New York, NY
Click here to add this to my saved trials
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated:  1/21/2016
Aerie Clinical Operations
mi
from
Bedminster, NJ
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
Status: Enrolling
Updated: 1/21/2016
Aerie Clinical Operations
mi
from
Bedminster, NJ
Click here to add this to my saved trials
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  1/22/2016
Neuro-Ophthalmologic Associates, PC
mi
from
Philadelphia, PA
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 1/22/2016
Neuro-Ophthalmologic Associates, PC
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca
Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca.
Status: Enrolling
Updated:  1/25/2016
Baylor College of Medicine, Alkek Eye Center
mi
from
Houston, TX
Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca
Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca.
Status: Enrolling
Updated: 1/25/2016
Baylor College of Medicine, Alkek Eye Center
mi
from
Houston, TX
Click here to add this to my saved trials
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
Status: Enrolling
Updated:  1/25/2016
Kellogg Eye Center
mi
from
Ann Arbor, MI
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
Status: Enrolling
Updated: 1/25/2016
Kellogg Eye Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft in Patients With a History of Allergic Conjunctivitis
Status: Enrolling
Updated:  1/26/2016
Derek Cunningham
mi
from
Austin, TX
A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft in Patients With a History of Allergic Conjunctivitis
Status: Enrolling
Updated: 1/26/2016
Derek Cunningham
mi
from
Austin, TX
Click here to add this to my saved trials
The Pathogenesis of Idiopathic Dry Eyes
Status: Enrolling
Updated:  1/26/2016
University of Michigan/Kellogg Eye Center
mi
from
Ann Arbor, MI
The Pathogenesis of Idiopathic Dry Eyes
Status: Enrolling
Updated: 1/26/2016
University of Michigan/Kellogg Eye Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Los Angeles Clinical Site 110
mi
from
Los Angeles, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Los Angeles Clinical Site 110
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Mission Hills Clinical Site
mi
from
Mission Hills, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Mission Hills Clinical Site
mi
from
Mission Hills, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Newport Beach Clinical Site
mi
from
Newport Beach, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Newport Beach Clinical Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Pasadena Clinical Site
mi
from
Pasadena, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Pasadena Clinical Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Petaluma Clinical Site - Site 05
mi
from
Petaluma, CA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Petaluma Clinical Site - Site 05
mi
from
Petaluma, CA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Morrow Clinical Site
mi
from
Morrow, GA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Morrow Clinical Site
mi
from
Morrow, GA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Roswell Clinical Site
mi
from
Roswell, GA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Roswell Clinical Site
mi
from
Roswell, GA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
New York Clinical Site
mi
from
New York, NY
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
New York Clinical Site
mi
from
New York, NY
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
High Point Clinical Site - Site 06
mi
from
High Point, NC
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
High Point Clinical Site - Site 06
mi
from
High Point, NC
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Cranberry Township Clinical Site
mi
from
Cranberry Township, PA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Cranberry Township Clinical Site
mi
from
Cranberry Township, PA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Philadelphia Clinical Site 120
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated:  1/26/2016
Austin Clinical Site
mi
from
Austin, TX
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Status: Enrolling
Updated: 1/26/2016
Austin Clinical Site
mi
from
Austin, TX
Click here to add this to my saved trials
Comparison of Systane Free vs. Saline in the Treatment of Dry Eye
Comparison of Systane Free vs. Saline in the Treatment of Dry Eye
Status: Enrolling
Updated:  1/26/2016
Southern California Colleg of Optometry
mi
from
Fullerton, CA
Comparison of Systane Free vs. Saline in the Treatment of Dry Eye
Comparison of Systane Free vs. Saline in the Treatment of Dry Eye
Status: Enrolling
Updated: 1/26/2016
Southern California Colleg of Optometry
mi
from
Fullerton, CA
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Harvard Eye Associates
mi
from
Laguna Hills, CA
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Harvard Eye Associates
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Hull Eye Center
mi
from
Lancaster, CA
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Hull Eye Center
mi
from
Lancaster, CA
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Argus Research
mi
from
Cape Coral, FL
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Argus Research
mi
from
Cape Coral, FL
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Levenson Eye Associates
mi
from
Jacksonville, FL
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Levenson Eye Associates
mi
from
Jacksonville, FL
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Chicago Cornea Consultants, LTD
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
JacksonEye
mi
from
Lake Villa, IL
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
JacksonEye
mi
from
Lake Villa, IL
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Discover Vision Centers
mi
from
Leawood, KA
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Discover Vision Centers
mi
from
Leawood, KA
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Opthalmic Consultants of Boston
mi
from
Waltham, MA
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Opthalmic Consultants of Boston
mi
from
Waltham, MA
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Talamo Hatch Laser Eye Consultants
mi
from
Waltham, MA
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Talamo Hatch Laser Eye Consultants
mi
from
Waltham, MA
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Associated Eye Care
mi
from
Stillwater, MN
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Associated Eye Care
mi
from
Stillwater, MN
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Comprehensive Eye Care Ltd
mi
from
Washington, MO
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Comprehensive Eye Care Ltd
mi
from
Washington, MO
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Alterman, Modi and Wolter
mi
from
Poughkeepsie, NY
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Alterman, Modi and Wolter
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
Cincinnati Eye Institute
mi
from
Cincinnati, OH
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
Cincinnati Eye Institute
mi
from
Cincinnati, OH
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
R and R Eye Research, LLC
mi
from
San Antonio, TX
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
R and R Eye Research, LLC
mi
from
San Antonio, TX
Click here to add this to my saved trials
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated:  1/27/2016
See Clearly Vision Group
mi
from
McLean, VA
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery
Status: Enrolling
Updated: 1/27/2016
See Clearly Vision Group
mi
from
McLean, VA
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
Sall Research Medical Center, Inc.
mi
from
Artesia, CA
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
North Bay Eye Associates
mi
from
Petaluma, CA
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
North Bay Eye Associates
mi
from
Petaluma, CA
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
Eye Care Centers Management/Clayton Eye Center
mi
from
Morrow, GA
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
Eye Care Centers Management/Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
Taustin Eye Center
mi
from
Louisville, KY
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
Taustin Eye Center
mi
from
Louisville, KY
Click here to add this to my saved trials
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  1/27/2016
East Tallin Central Hospital
mi
from
Tallin,
SYL040012, Treatment for Open Angle Glaucoma
A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 1/27/2016
East Tallin Central Hospital
mi
from
Tallin,
Click here to add this to my saved trials